Huadong Historical Income Statement

000963 Stock

32.63 0.25 0.77%

Historical analysis of Huadong Medicine income statement accounts such as Selling General Administrative of 6.1 B, Total Revenue of 49.1 B or Operating Income of 4.5 B can show how well Huadong Medicine Co performed in making a profits. Evaluating Huadong Medicine income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Huadong Medicine's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Huadong Medicine latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Huadong Medicine is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Huadong Medicine Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About Huadong Income Statement Analysis

Huadong Medicine Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Huadong Medicine shareholders. The income statement also shows Huadong investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Huadong Medicine Income Statement Chart

At present, Huadong Medicine's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 6.1 B, whereas Minority Interest is projected to grow to (8.2 M).

Selling General Administrative Total Revenue Operating Income Cost Of Revenue Ebit Tax Provision

Total Revenue

Total revenue comprises all receipts Huadong Medicine generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Operating Income

Operating Income is the amount of profit realized from Huadong Medicine operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Huadong Medicine Co is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Cost Of Revenue

Cost of Revenue is found on Huadong Medicine income statement and represents the costs associated with goods and services Huadong Medicine provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Most accounts from Huadong Medicine's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Huadong Medicine current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Huadong Medicine Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

	2022	2023	2024	2025 (projected)
Operating Income	3.3B	3.8B	4.3B	4.5B
Total Revenue	37.7B	40.6B	46.7B	49.1B

Operating Income Total Revenue

Huadong Medicine income statement Correlations

	Selling General Administrative	Total Revenue	Operating Income	Cost Of Revenue	Income Before Tax	Net Income	Income Tax Expense	Minority Interest	Research Development	Gross Profit	Other Operating Expenses	Net Income From Continuing Ops	Ebit	Total Operating Expenses	Total Other Income Expense Net	Tax Provision	Net Interest Income	Interest Income	Ebitda	Reconciled Depreciation
Selling General Administrative		0.92	0.93	0.91	0.94	0.94	0.96	0.11	0.85	0.85	0.86	0.89	0.9	0.83	0.84	0.79	0.75	0.68	0.86	0.67
Total Revenue	0.92		0.99	1.0	0.98	0.97	0.96	-0.06	0.87	0.88	0.9	0.88	0.9	0.89	0.83	0.87	0.59	0.74	0.86	0.78
Operating Income	0.93	0.99		0.98	0.99	0.99	0.97	-0.04	0.89	0.91	0.92	0.92	0.93	0.92	0.85	0.9	0.61	0.74	0.9	0.78
Cost Of Revenue	0.91	1.0	0.98		0.96	0.96	0.96	-0.04	0.83	0.85	0.87	0.85	0.87	0.86	0.82	0.84	0.56	0.71	0.82	0.75
Income Before Tax	0.94	0.98	0.99	0.96		1.0	0.98	0.07	0.89	0.91	0.92	0.94	0.94	0.9	0.88	0.9	0.66	0.69	0.9	0.73
Net Income	0.94	0.97	0.99	0.96	1.0		0.98	0.05	0.9	0.92	0.93	0.95	0.95	0.91	0.88	0.91	0.67	0.71	0.91	0.75
Income Tax Expense	0.96	0.96	0.97	0.96	0.98	0.98		0.17	0.85	0.86	0.88	0.91	0.92	0.85	0.91	0.84	0.68	0.63	0.84	0.65
Minority Interest	0.11	-0.06	-0.04	-0.04	0.07	0.05	0.17		-0.12	-0.15	-0.12	0.07	0.02	-0.2	0.19	-0.11	0.1	-0.53	-0.1	-0.51
Research Development	0.85	0.87	0.89	0.83	0.89	0.9	0.85	-0.12		0.98	0.95	0.95	0.95	0.97	0.75	0.96	0.7	0.84	0.95	0.89
Gross Profit	0.85	0.88	0.91	0.85	0.91	0.92	0.86	-0.15	0.98		0.98	0.97	0.97	0.99	0.79	0.97	0.69	0.87	0.97	0.91
Other Operating Expenses	0.86	0.9	0.92	0.87	0.92	0.93	0.88	-0.12	0.95	0.98		0.96	0.98	0.99	0.85	0.96	0.64	0.86	0.93	0.89
Net Income From Continuing Ops	0.89	0.88	0.92	0.85	0.94	0.95	0.91	0.07	0.95	0.97	0.96		0.99	0.95	0.86	0.96	0.72	0.74	0.96	0.79
Ebit	0.9	0.9	0.93	0.87	0.94	0.95	0.92	0.02	0.95	0.97	0.98	0.99		0.96	0.88	0.94	0.68	0.77	0.94	0.81
Total Operating Expenses	0.83	0.89	0.92	0.86	0.9	0.91	0.85	-0.2	0.97	0.99	0.99	0.95	0.96		0.79	0.97	0.65	0.88	0.95	0.93
Total Other Income Expense Net	0.84	0.83	0.85	0.82	0.88	0.88	0.91	0.19	0.75	0.79	0.85	0.86	0.88	0.79		0.76	0.65	0.57	0.7	0.57
Tax Provision	0.79	0.87	0.9	0.84	0.9	0.91	0.84	-0.11	0.96	0.97	0.96	0.96	0.94	0.97	0.76		0.63	0.8	0.95	0.88
Net Interest Income	0.75	0.59	0.61	0.56	0.66	0.67	0.68	0.1	0.7	0.69	0.64	0.72	0.68	0.65	0.65	0.63		0.5	0.69	0.5
Interest Income	0.68	0.74	0.74	0.71	0.69	0.71	0.63	-0.53	0.84	0.87	0.86	0.74	0.77	0.88	0.57	0.8	0.5		0.8	0.97
Ebitda	0.86	0.86	0.9	0.82	0.9	0.91	0.84	-0.1	0.95	0.97	0.93	0.96	0.94	0.95	0.7	0.95	0.69	0.8		0.85
Reconciled Depreciation	0.67	0.78	0.78	0.75	0.73	0.75	0.65	-0.51	0.89	0.91	0.89	0.79	0.81	0.93	0.57	0.88	0.5	0.97	0.85

Click cells to compare fundamentals

Huadong Medicine Account Relationship Matchups

Huadong Medicine income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Interest Expense	68.6M	72.5M	125.1M	114.9M	132.1M	138.7M
Selling General Administrative	6.4B	5.9B	6.9B	5.1B	5.9B	6.1B
Total Revenue	33.7B	34.6B	37.7B	40.6B	46.7B	49.1B
Operating Income	3.2B	3.0B	3.3B	3.8B	4.3B	4.5B
Cost Of Revenue	22.6B	24.0B	25.7B	27.5B	31.6B	33.2B
Income Before Tax	3.5B	2.8B	3.0B	3.5B	4.0B	4.2B
Net Income Applicable To Common Shares	2.3B	2.8B	2.8B	2.3B	2.6B	2.8B
Net Income	2.8B	2.3B	2.5B	2.8B	3.3B	3.4B
Income Tax Expense	477.4M	544.9M	543.7M	488.9M	562.2M	590.4M
Minority Interest	559.6M	(37.0M)	(33.4M)	(7.5M)	(8.7M)	(8.2M)
Research Development	926.7M	979.6M	1.0B	1.3B	1.5B	809.4M
Gross Profit	11.1B	10.6B	12.0B	13.2B	15.1B	10.5B
Other Operating Expenses	180.9M	184.4M	176.1M	205.3M	236.1M	183.8M
Net Income From Continuing Ops	2.9B	2.3B	2.5B	2.8B	3.3B	2.5B
Ebit	3.2B	3.0B	2.8B	3.2B	3.6B	2.9B
Total Operating Expenses	30.4B	31.5B	34.4B	36.9B	42.4B	32.0B
Tax Provision	543.7M	488.9M	498.5M	619.6M	712.5M	543.9M
Net Interest Income	(24.2M)	(22.1M)	(43.6M)	(46.8M)	(53.9M)	(56.6M)
Interest Income	61.0M	80.4M	103.4M	94.0M	108.2M	64.0M
Ebitda	4.0B	4.0B	3.5B	3.9B	4.4B	3.9B
Reconciled Depreciation	431.0M	591.6M	705.5M	809.6M	931.0M	555.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Other Information on Investing in Huadong Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Huadong Historical Income Statement

About Huadong Income Statement Analysis

Huadong Medicine Income Statement Chart

Total Revenue

Operating Income

Cost Of Revenue

Tax Provision

Huadong Medicine income statement Correlations

Huadong Medicine Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Huadong Medicine income statement Accounts

Also Currently Popular

Other Information on Investing in Huadong Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cost Of Revenue	+ 1.0	Total Revenue
Net Income	+ 1.0	Income Before Tax
Operating Income	+ 0.99	Total Revenue
Income Before Tax	+ 0.99	Operating Income
Net Income	+ 0.99	Operating Income
Total Operating Expenses	+ 0.99	Gross Profit

Interest Income	- 0.53	Minority Interest
Reconciled Depreciation	- 0.51	Minority Interest
Total Operating Expenses	- 0.2	Minority Interest
Gross Profit	- 0.15	Minority Interest
Other Operating Expenses	- 0.12	Minority Interest
Research Development	- 0.12	Minority Interest